156 related articles for article (PubMed ID: 7870216)
1. Correlation of cytosolic concentrations of ER, PS2, Cath-D, TPS, TK and cAMP in primary breast carcinomas.
Kausitz J; Kuliffay P; Pecen L; Eben K; Puterová B
Neoplasma; 1994; 41(6):331-6. PubMed ID: 7870216
[TBL] [Abstract][Full Text] [Related]
2. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].
Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A
Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070
[TBL] [Abstract][Full Text] [Related]
3. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
[TBL] [Abstract][Full Text] [Related]
5. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
[TBL] [Abstract][Full Text] [Related]
6. Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen.
Dittadi R; Biganzoli E; Boracchi P; Salbe C; Mione R; Gatti C; Gion M
Int J Biol Markers; 1998; 13(1):30-41. PubMed ID: 9681297
[TBL] [Abstract][Full Text] [Related]
7. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
[TBL] [Abstract][Full Text] [Related]
8. pS2 protein status fails to be an independent prognostic factor in an average breast cancer population.
Speiser P; Stolzlechner J; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeilliger R
Anticancer Res; 1994; 14(5B):2125-30. PubMed ID: 7840511
[TBL] [Abstract][Full Text] [Related]
9. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
[TBL] [Abstract][Full Text] [Related]
10. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.
Pujol P; Daurès JP; Brouillet JP; Maudelonde T; Rochefort H; Grenier J
Br J Cancer; 1999 Feb; 79(5-6):909-14. PubMed ID: 10070889
[TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay].
Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M
Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210
[TBL] [Abstract][Full Text] [Related]
12. [Cytosolic pS2 levels in 154 non-small-cell lung carcinomas. Correlation with other clinical and biological parameters].
Ruibal A; Núñez MI; del Río MC; García Díez S; Rodríguez J; Alvarez De Linera JA
Rev Esp Med Nucl; 2002 Apr; 21(2):109-14. PubMed ID: 11879619
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of the cytosolic content of the pS2 protein in breast cancer].
Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT
Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999
[TBL] [Abstract][Full Text] [Related]
14. Biochemical parameters for prognostic evaluation in patients with breast cancer.
Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Sampognaro E; Meo S
Anticancer Res; 1994; 14(2B):693-8. PubMed ID: 8010728
[TBL] [Abstract][Full Text] [Related]
15. Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation.
Coradini D; Biganzoli E; Boracchi P; Bombardieri E; Seregni E; De Palo G; Martelli G; Di Fronzo G
Int J Cancer; 1998 Aug; 79(4):305-11. PubMed ID: 9699519
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-regulated cut-off values of pS2 and cathepsin D expression in breast carcinomas.
Markićević M; Petrović A; Kanjer K; Nesković-Konstantinović Z; Nikolić-Vukosavujević D
Adv Exp Med Biol; 2008; 617():341-8. PubMed ID: 18497057
[TBL] [Abstract][Full Text] [Related]
17. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors.
Valerón PF; Chirino R; Vega V; Falcón O; Rivero JF; Torres S; León L; Fernández L; Pestano J; Díaz-Chico B; Díaz-Chico JC
Int J Cancer; 1997 Apr; 74(2):175-9. PubMed ID: 9133451
[TBL] [Abstract][Full Text] [Related]
19. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.
Racca S; Conti G; Pietribiasi F; Stramignoni D; Tampellini M; Valetto MR; Ghezzo F; Di Carlo F
Int J Biol Markers; 1995; 10(2):87-93. PubMed ID: 7561244
[TBL] [Abstract][Full Text] [Related]
20. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity.
Correale M; Paradiso A; Abbate I; Mangia A; Dragone CD; Tedone T; Filotico R; Schittulli F; De Lena M
Tumour Biol; 1993; 14(1):30-7. PubMed ID: 8493448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]